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E D I T O R I A L
From the vulnerable plaque to the vulnerable patient: Current
concepts in atherosclerosis
Cardiovascular disease affects a significant proportion of the popula-
tion with global prevalence of 6,081 per 100,000 (Virani et al., 2020).
Most core risk factors are well characterised and can be controlled
with interventions, also meaning it is possible to identify most people
at increased risk of acute events, defined as a 10-year risk of events
of >20%. However, the real-world occurrence of events in this at-risk
population is relatively low suggesting there is still much to be learnt
or identified in spotting the vulnerable patient harbouring vulnerable
atherosclerotic plaque at the earliest possible time.
The development of atherosclerotic plaque spans people's
lifetime. The risk of developing cardiovascular disease (CVD) can be
estimated as a roughly equal balance of genetically inherited suscepti-
bility and exposure to environmental risk factors. Increasingly, the
complexity of coronary artery disease (CAD), as the archetypal CVD,
is underlined by the fact that a large number of genes or gene sets
comprising up to 14% of genes in the genome can be linked to func-
tionally influencing CAD development (Nikpay et al., 2020), through
the association of genetic variants with CAD risk in large international
cohorts. The majority of these variants play a small role (e.g. 2–5%
effect size) (Howson et al., 2017) and so, which novel gene products
to target therapeutically remains a question that must be answered
with future studies.
Atherosclerosis is almost universally present and is a long-
standing pathology. Fundamentally, plaque develops as a result of a
maladaptive response of the artery wall and infiltrating immune cells
to accumulation and modification of lipoprotein, such as low density
lipoprotein (LDL) and lipoprotein(a) (Lp[a]) (Lichtman et al., 2013).
Well-characterised risk factors, in addition to the circulating LDL level,
are blood pressure, systemic inflammation, diabetes and obesity
(Yusuf et al., 2004). Thus, the concept of vulnerable patients can be
described as patients presenting with a combination of multiple risk
factors and/or extremely high risk levels of one of these core risks
(Naghavi et al., 2003). All these risk factors feed into the core
interaction between LDL, vascular cells responding to the injurious
accumulation and oxidative modification of LDL trapped in the sub-
endothelial space, along with the invasion of myeloid cells and T cells
that can either promote progression or resolution of plaque
inflammation (reviewed in Tabas & Lichtman, 2017). In the last 30
years, there has been a growing recognition that some specific charac-
teristics of atherosclerotic plaques, which make the plaque more
prone to trigger thrombotic events, are far more important clinically
than absolute size or level of lumen occlusion (Finn et al., 2010). For
example, the majority of events in the SCOT-HEART study were not
triggered by the presence of occlusive disease (Investigators
et al., 2018). Thus, the concept of vulnerable plaques is the focus of
endeavours in the field. This review series focuses on advances critical
to the identification, mechanistic understanding and treatment of
vulnerable patients, and the vulnerable plaques that trigger adverse
events. These articles were commissioned leading on from a British
Atherosclerosis Society meeting entitled “From the vulnerable plaque
to the vulnerable patient.”
Vulnerable plaques are not all the same. Thin-cap fibroatheroma,
defined as a fibrous cap and evidence of macrophage infiltration, is
prone to rupture. Another form of advanced plaque is rather prone
to erosion. The increased use of statins has led to a shift from
thin-cap fibroatheroma to plaque erosions over time (Libby &
Pasterkamp, 2015). Originally defined by histology, defining vulnera-
ble plaques in at-risk (vulnerable) patients is now possible using a raft
of imaging techniques including PET, CT, MRI and intravascular ultra-
sound. Characterising a patient's actual arteries is a powerful tool
essential in formally quantifying the burden of disease. Now multiple
modalities are available in the research setting and increasingly in
routine clinical practice. Two complementary reviews from Sriranjan
et al. (Sriranjan et al., 2021) and Daghem and Newby (Daghem &
Newby, 2021) review the use PET and CT in assessing vulnerable
patients and defining vulnerable plaques.
PET utilises radiotracers binding molecular targets to gain a
detailed characterisation of body tissues non-invasively. It has most
extensively been used in oncology but with the development of
instrumentation and availability of novel radiolabelled probes is now
used in other areas including, prominently, in CVD patients. PET
enables labelling of, for example, glucose incorporation and the
presence of macrophages. In their review, Sriranjan et al. (2021) dis-
cuss the advances in PET usage for assessing vulnerable plaques and
the results of trials using PET imaging. Fluorodeoxy-glucose has been
used both in prognostic investigations and in interventional trials, par-
ticularly in those aiming to target inflammation directly. The range of
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PET ligands used to investigate plaque characteristics is growing and
the leading candidates, such as DOTATATE are discussed further in
their review.
CT is an X-ray-based technique for fine detail discrimination of
tissue morphology. Daghem and Newby (Daghem & Newby, 2021)
review the importance of CT in cardiology. The detection of calcifica-
tion and its use in quantifying plaque burden has been a major
breakthrough achieved with non-invasive imaging. Despite limitations
in this method as a means to quantify disease burden, there is yet to
be a CT study adding better prognostic value. New innovations and
trials are building on developing the prognostic potential of CT and its
use in combination with PET.
Smooth muscle cells (SMCs) are central players in atherosclerosis.
During the development of the disease, these cells transition from a
quiescent layer of cells encased in elastin fibres maintaining vessel
function to proliferative, matrix-secreting cells that contribute to both
adverse and beneficial plaque processes (Basatemur et al., 2019).
Harman and Jorgensen (Harman & Jorgensen, 2019) review the many
important contributions of SMCs to plaque vulnerability, new
techniques to understand and modify SMC functions and future
modalities that could target them therapeutically. SMCs are now
recognised to play a prominent and diverse set of roles in plaque for-
mation, with differentiation into macrophage-like cells, osteoblasts
and foam cells, and, in adventitial regions, lymphoid tissue organiser
cells (Hu et al., 2015) are all possible. In terms of the critical process of
plaque vulnerability, vascular smooth muscle cells (VSMCs) play a
unique role in secretin extracellular matrix that maintains the integrity
of the fibrous cap. However, in addition to macrophages, VSMCs also
produced matrix-degrading cytokines that might trigger cap thinning.
VSMCs are thought to be key to calcification, which also has impor-
tant consequence for plaque vulnerability. Harman and Jorgensen
(Harman & Jorgensen, 2019) also elucidate novel techniques now
available to track in more detail the lineage of plaque SMC-derived
cells and in identifying the herterogeneity of the culprit VSMCs that
actually respond to the early injury responses triggering plaque
formation.
Vulnerable patients may develop multiple plaques with vulnerable
features compared to those without and so need more aggressive
treatment at an earlier disease stage. LDL has proven an effective
targeting modality. Statins reduce the risk of events in multiple large
trials and, although may have some pleiotropic effects, the absolute
reduction in LDL is strongly linked to the reduction of risk. However,
side effects and lack of efficacy in some patients preclude the univer-
sal use of statins and highlight the need for competitive alternatives.
The growing recognition of lipoprotein(a) as an additional risk factor
has meant drugs that can also target lipoprotein(a) are required and
under evaluation (Tsimikas, 2016). Familial hypercholesterolemia
patients are among the most vulnerable, given the high lifetime bur-
den of exposure to LDL (Ference et al., 2018). Proprotein convertase
subtilisin/kexin type 9 (PCSK9) regulates LDL receptors at the protein
level and is now established as novel drug target to control
atherogenic lipids. Nishikido and Ray (Nishikido & Ray, 2021) review
the current state of the field of lipid lowering, how lipid targeting may
be key in treating the vulnerable patient, and the changes made
possible with the discovery of PCSK9.
Integration of imaging information on precursor lesions with systemic
and genetic risk factors can help to build a more refined and
personalised risk model for the vulnerable patient and these
innovative advances are coming online with increasing pace. How-
ever, studies suggest that event-triggering thrombosis following a
plaque rupture may actually be relatively rare and that many rupture
events are clinically silent and lead to establishment of a more stable
“healed” plaque phenotype (Sriranjan et al., 2021). We need more
work to pinpoint the truly vulnerable plaque.
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